LEGN Legend Biotech

$LEGN added about $150K more here. I’ll add more if it goes lower to retest the low to mid 16’s. My favorite time to buy biotechs is at stupid low prices. I think this qualifies now given their commercial success and pipeline. I didn’t think we would see these prices again after the release of their in vivo data but here we are.

$LEGN It amazes me to see companies without any products can be worth several billion dollars. While LEGN with a blockbuster drug with will be >4 billion revenue and a rich pipeline is only at a market cap of 3.7 billion. If not for LEGN, it is possible that the pipeline alone can put the company at the current market cap, meaning the will be close to 4 billion dollars revenue is only worth zero or a negative value. God, give us a fair value of 40-60 dollars a share already!

$LEGN Carvykti can make >4 billion in 2027. LEGN will get 50% of the 4 billion to have 2 billion. The market cap of only 3.7b is unbelievable What about the rich pipeline???? In my mind, the market should be at a minimum of >6 billion, meaning share price of >40. Hope we will see some levels of correction in the remaining of 2026 and 2027.

$LEGN Her primary responsibility will be accelerating the commercial footprint of Legend's flagship cell therapy Just sell the company

$LEGN Hiring Zhang is a good move 1. Her connection with Novartis can put pressure on JJ. It is like an insider for Novartis, plus the two (LEGN and Novartis) already have some sort of collaboration. JJ may have played a hardball in the past , now LEGN has a way to counter 2. She has a lot of commercial experience, which can maximize the value of Carvykti globally. A blockbuster drug and a very promising pipeline will ultimately reward investors.

$LEGN I believe this devaluation of stock price is due to the terms and conditions of the partnership between legend and JNJ, …JNJ is playing hard ball, they want to swallow legend for nothing, useless board, incompetent management team, the entire crew needs firing

$LEGN On X:The Kenyan Bull My latest buy: Legend Biotech. Thesis: the market has undervalued the structural growth of CARVYKTI. I think that with the bottlenecks out of the way, $LEGN is poised to soar. I expect this stock to at least trade at $35, even with Gilead chasing a piece of the market.

$LEGN Oppenheimer noted that just 4 months after presenting similar data to the LEGN In-Vivo data dropped 3 months ago LLY ponied up $7 Billion for Kelonia Therapeutics. Oppy said: “Positive In-Vivo CART data strengthens chances of LEGN acquisition in our view”.

$LEGN Under her leadership in 2023, the China division grew by 17% year-over-year; before her promotion to the global team, she successfully secured crucial national reimbursement coverage in China for Novartis's blockbuster breast cancer drug, Kisqali. Navigating China's National Reimbursement Drug List (NRDL) requires heavy institutional influence and deep localized strategy

$LEGN NVS going after LEGN IN-VIVO partnership? For the thesis to become more credible, I would look for disclosures involving terms such as “in-vivo cell therapy,” “next-generation CAR-T,” “strategic alternatives,” “business development,” “platform collaboration,” or a new Legend pipeline program involving targeted delivery or in-body T-cell engineering. Without one of those signals, the Zhang appointment is better viewed as a potential relationship catalyst, not confirmation of a Novartis transaction. Look for color next week at the conference 23rd-26th.

$LEGN I’m almost thinking at this point why doesn’t Legend buy Carvykti full ownership rights from JNJ. Clearly JnJ isn’t prioritizing Carvykti as much as it did before.

$LEGN FFS why do we keep droping...LEGN EV value is bellow 3 bil at this point with the cash on hand we have. I mean Q1 2027 could start with 1bil per quarter, then this is already at 6bil on 3x multiple without even counting that with expansion we could climb way faster. Without any invivo value added... If this isn't 60$ per share by h1 2027 I give up on this stock.

$LEGN Think what you want: but giving the CEO news scoop exclusively to WSJ, while disregarding other biotech industry-specific news sites says something about company’s (boards) intentions. They are aiming for bigger prize, either through internal breakthroughs or through external financial events (major pharma M&A)

$LEGN The new CEO did not instill trust of the market, yet. I guess Ingrid Zhang needs to deliver first, before SP moves up again. And she is Chinese? Market seems a bit skeptical to have too many bonds with China, even though $LEGN is listed in the US, their origins, key ownership and major operations are from China. And now a Chinese CEO? Market Cap seems super low at these prices, but the complex deal structure with J&J also means that only half of the profits from CARVYKTI sales stay with $LEGN. I am sure, in the long run SP will move up, but it may take some time.

$LEGN I feel like this is the kind of action you see right before a stock gets taken out. Kind of reminds me of Celgene collapsing before it got purchased by Bristol.

$LEGN Valuation cries for a starter, but the stock Performance really holds me back. They really scare the life out of shareholders on this one.

$LEGN Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.

$LEGN Novartis is paying $575 million upfront for Abogen's in-vivo mRNA T-cell engager, ABO2203. Total milestones reach $7.2 billion, plus royalties. The target is CD19xCD3 for autoimmune indications, delivered via lipid nanoparticles to generate bispecific engagers directly inside the patient. The deal validates in-vivo T-cell redirection as a direct threat to ex-vivo autologous CAR-T. By having the patient's own liver or immune cells produce the CD19 engager from synthetic mRNA, Novartis bypasses leukapheresis, viral vectors, and multi-week vein-to-vein turnarounds entirely. Autologous cell therapy platforms pushing into lupus and sclerosis now face an incumbent willing to price in-vivo convenience at half a billion in cash before clinical proof of concept. Watch Phase 1 PK/PD readouts to see whether transient mRNA expression can match the deep, reset-level B-cell depletion achieved by cellular infusion.

$LEGN Carvykti's label puts parkinsonism at 6% of patients in its original pivotal trial, CARTITUDE-1, and 1% in the later CARTITUDE-4. In the pivotal trial of Gilead's anito-cel, 117 patients, the reported count is zero. The FDA's target date for anito-cel, in patients after three or more prior lines, is December 23. Carvykti's boxed warning names parkinsonism and Guillain-Barré syndrome. The test for anito-cel's label is whether it mentions either one at all. Anito-cel would start in fourth line, with safety as its pitch. The next fight is for earlier line. The bigger risk for Legend is iMMagine-3. Gilead finished enrolling iMMagine-3, anito-cel against standard regimens after one to three prior lines, in the second quarter and says it could file as early as 2027. Gilead paid about $7.8 billion for Arcellx and will pay $5 a share more if anito-cel sells $6 billion from launch through 2029. If the FDA approves in December, that means averaging about $2 billion a year.

$LEGN Novartis signed a major deal with a Chinese biotech for mRNA based T cell engagers (TCE) to treat autoimmune diseases. TCEs or mRNA modalities are alternatives for lentiviral-based in vivo CAR-T to target autoimmune indications.